Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: Bridging a gap between clinical trials and clinical practice

Annals of the Rheumatic Diseases

Volumn 69, Issue 2, 2010, Pages 374-379

  Moore, R A ^a   Moore, O A ^b   Derry, S ^a   Peloso, P M ^c   Gammaitoni, A R ^c   Wang, H ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b MUSGROVE PARK HOSPITAL   (United Kingdom)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; ETORICOXIB; IBUPROFEN; NAPROXEN; PLACEBO;

ANALGESIA; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; META ANALYSIS; OSTEOARTHRITIS; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

CYCLOOXYGENASE 2 INHIBITORS; DIFFUSION OF INNOVATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; PAIN; PAIN MEASUREMENT; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONES; TREATMENT OUTCOME;

EID: 75749113330     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2009.107805     Document Type: Article

References (36)

1. Christakis NA. Does this work for you? BMJ 2008;337:a2281.
2. Moore RA, Straube S, Derry S, et al. Does this work for you? Individuals, averages, and evidence based medicine. BMJ 2008;337:a2585
3. Moore RA, Edwards JE, McQuay HJ. Acute pain: individual patient meta-analysis shows the impact of different ways of analysing and presenting results. Pain 2005;116:322-31.
4. Finnerup NB, Otto M, McQuay HJ, et al. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005;118:289-305.
5. Straube S, Derry S, McQuay HJ, et al. Enriched enrolment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review. Br J Clin Pharmacol 2008;66:266-75.
6. Sultan A, Gaskell H, Derry S, et al. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurol 2008;8:29.
7. Dahlof CG, Pascual J, Dodick DW, et al. Efficacy, speed of action and tolerability of almotriptan in the acute treatment of migraine: pooled individual patient data from four randomized, double-blind, placebo-controlled clinical trials. Cephalalgia 2006;26:400-8.
8. Geborek P, Crnkic M, Petersson IF, et al, South Swedish Arthritis Treatment Group. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002;61:793-8.
9. Moore RA, Moore OA, Derry S, et al. Numbers needed to treat calculated from responder rates give a better indication of efficacy in osteoarthritis trials than mean pain scores. Arthritis Res Ther 2008;10:R39.
10. Fries S, Grosser T, Price TS, et al. Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Gastroenterology 2006;130:55-64.
11. Klepstad P, Dale O, Skorpen F, et al. Genetic variability and clinical efficacy of morphine. Acta Anaesthesiol Scand 2005;49:902-8.
12. Lötsch J, Geisslinger G. Current evidence for a genetic modulation of the response to analgesics. Pain 2006;121:1-5.
13. Wessels JA, van der Kooij SM, le Cessie S, et al, Pharmacogenetics Collaborative Research Group. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum 2007;56:1765-75.
14. Harvey VL, Dickenson AH. Mechanisms of pain in nonmalignant disease. Curr Opin Support Palliat Care 2008;2:133-9.
15. Baliki MN, Geha PY, Apkarian AV, et al. Beyond feeling: chronic pain hurts the brain, disrupting the default-mode network dynamics. J Neurosci 2008;28:1398-403.
16. Tracey I. Neuroimaging of pain mechanisms. Curr Opin Support Palliat Care 2007;1:109-16.
17. McQuay HJ, Carroll D, Moore RA. Variation in the placebo effect in randomised controlled trials of analgesics: all is as blind as it seems. Pain 1996;64:331-5.
18. Moore RA, McQuay H. Single-patient data meta-analysis of 3,453 postoperative patients: oral tramadol versus placebo, codeine and combination analgesics. Pain 1997;69:287-94.
19. Farrar JT, Dworkin RH, Max MB. Use of the cumulative proportion of responders analysis graph to present pain data over a range of cut-off points: making clinical trial data more understandable. J Pain Symptom Manage 2006;31:369-77.
20. McQuay HJ, Moore RA. Using numerical results from systematic reviews in clinical practice. Ann Intern Med 1997;126:712-20.
21. Gottesdiener K, Schnitzer T, Fisher C, et al, Protocol 007 Study Group. Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis. Rheumatology (Oxford) 2002;41:1052- 61.
22. Reginster JY, Malmstrom K, Mehta A, et al. Evaluation of the efficacy and safety of etoricoxib compared to naproxen in two, 138-week randomized studies of osteoarthritis patients. Ann Rheum Dis 2007;66:945-51.
23. Leung AT, Malmstrom K, Gallacher AE, et al. Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: a randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial. Curr Med Res Opin 2002;18:49-58.
24. Wiesenhutter CW, Boice JA, Ko A, et al, Protocol 071 Study Group. Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2005;80:470-9.
25. Puopolo A, Boice JA, Fidelholtz JL, et al. A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis. Osteoarthr Cartil 2007;15:1348-56.
26. Bingham CO, Sebba AI, Rubin BR, et al. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology (Oxford) 2007;46:496-507.
27. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008;9:105-21.
28. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995;310:452-4.
29. Morris JA, Gardner MJ. Calculating confidence intervals for relative risk, odds ratios and standardised ratios and rates. In: Gardner MJ, Altman DG, eds. Statistics with confidence - confidence intervals and statistical guidelines. London: BMJ, 1995:50-63.
30. Tramer MR, Reynolds DJ, Moore RA, et al. Impact of covert duplicate publication on meta-analysis: a case study. BMJ 1997;315:635-40.
31. Moore RA, Derry S, Makinson GT, et al. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther 2005;7:R644-65.
32. Moore RA, Derry S, McQuay HJ. Discontinuation rates in clinical trials in musculoskeletal pain: meta-analysis from etoricoxib clinical trial reports. Arthritis Res Ther 2008;10:R53.
33. McQuay HJ, Moore RA. Dose-response in direct comparisons of different doses of aspirin, ibuprofen and paracetamol (acetaminophen) in analgesic studies. Br J Clin Pharmacol 2007;63:271-8.
34. Moore RA, Gavaghan D, Tramèr MR, et al. Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain 1998;78:209-16.
35. Moore RA, Derry S, McQuay HJ, et al. What do we know about communicating risk? A brief review and suggestion for contextualising serious, but rare, risk, and the example of COX-2 selective and non-selective NSAIDs. Arthritis Res Ther 2008;10:R20.
36. Pham T, Van Der Heijde D, Lassere M, et al, OMERACT-OARSI. Outcome variables for osteoarthritis clinical trials: The OMERACT-OARSI set of responder criteria. J Rheumatol 2003;30:1648-54.